Alan F. List, MD, and James O. Armitage, MD, FACP, FRCP
Alan F. List, MD, of Moffitt Cancer Center and the University of South Florida, and James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, discuss the biology and diagnostic criteria for myelodysplastic syndrome, as well as advances in the disease presented at the 56th ASH Annual Meeting.
James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD
James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Richard M. Stone, MD of the Dana-Farber Cancer Institute, discuss three clinical trials: different doses of daunorubicin for AML; comparing azacitidine plus lenolidomide to vorinostat vs azacitidine monotherapy in MDS and CMML; and sorafenib vs placebo in addition to standard treatment for AML.